Skip to main content

Mark W. Grinstaff

NIH Rank #1103
  • Program Leader
  • R01 Holder
  • Top 10% Funded
  • Early Career
  • Mentor
  • Diverse Portfolio

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 1858385Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • CHEMISTRY
  • ENGINEERING (ALL TYPES)

NIH Funding · FY2024

Linked Award Amount
$5M
Full award amounts, FY2024
Award Records
9
Records listing this PI
Award-Linked Rank
#1,103
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Mark W. Grinstaff. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2024 NIH portfolio memberships

NIBIB

National Institute of Biomedical Imaging and Bioengineering

$0

1 awards · administering

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2024 award records by amount

NIH award records listing Mark W. Grinstaff as a PI. Multi-PI records show the full award amount for context.

  • 5R01CA272637-03R01
    Supratherapeutic PTX Buttresses Reduce Locoregional Recurrence Rates Following Surgery for Soft Tissue Sarcomas
    $676.4K
    award amount
  • 1R01DK141923-01R01
    Lysosomal Regeneration (LysoGen) and Rescue as a Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    $642.7K
    award amount
  • 5R01AR081264-03R01
    The Conundrum of Absentee Receptors: Efficacy Potentiation Through Drug-Receptor Modulation
    $629K
    award amount
  • 5R01AR079489-03R01
    Sustained Release Relaxin-2 for the Treatment of Frozen Shoulder
    $603.7K
    award amount
  • 5R01HL164650-03R01
    Sulfated Poly-Amido-Saccharide (sulPAS) Biomaterials as Anticoagulants
    $551.2K
    award amount
  • 5R01HL159644-03R01
    Biodegradable, Biocompatible Pressure Sensitive Adhesives
    $545.6K
    award amount
  • 1R01AR083161-01A1R01
    A Relaxin-loaded Hydrogel for the Treatment of Hypertrophic Scars
    $526K
    award amount
  • 5U01CA265713-04U01
    Precise tumor targeting with logic CAR circuits
    $525K
    award amount
  • 5T32EB006359-15T32
    Translational Research in Biomaterials
    $305.5K
    award amount

Award organizations

Organizations that administered FY2024 awards listing Mark W. Grinstaff as a PI.

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Boston University
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    $5M Cumulative Funding
  6. 2024
    Entered Top 50% Nationally
    Ranked #1103
  7. 2024
    Entered Top 25% Nationally
    Ranked #1103
  8. 2024
    Entered Top 10% Nationally
    Ranked #1103
  9. 2025
    $10M Cumulative Funding
  10. 2025
    Multi-Institutional Research
    Awards at 2 institutions
  11. 2025
    R01 Grant Holder
  12. 2025
    Program/Center Grant Leader